Tulasigeri Totiger
6PUBLICATIONS
86CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (6)
Sort by Publication Date:
|Nov 24, 2025
Co-targeting menin and LSD1 dismantles oncogenic programs and restores differentiation in MLL-rearranged AML.Mina M Tayari, Helena Gomes Dos Santos, Felipe Beckedorff
|Jul 30, 2025
XPO1 drives resistance to eprenetapopt and azacitidine and can be targeted in TP53-mutated myeloid malignancies.Traci L Kruer, Ariel Quintana, Hannah Newman
|Jun 18, 2025
XPO1 R749Q Mutations Co-occur with POLE Mutations in Cancer and Can Be Targeted to Overcome Chemoresistance.Tulasigeri M Totiger, Wannasiri Chiraphapphaiboon, Yasmine Baca
|Feb 01, 2024
Kinase-impaired BTK mutations are susceptible to clinical-stage BTK and IKZF1/3 degrader NX-2127.Skye Montoya, Jessie Bourcier, Mark Noviski
|Feb 25, 2023
Targeted Therapy Development in Acute Myeloid Leukemia.Tulasigeri M Totiger, Anirban Ghoshal, Jenna Zabroski
|Jan 10, 2023
Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.Benjamin Diamond, Bachisio Ziccheddu, Kylee Maclachlan
Pageof 1
Frequent Collaborators
6 joint publications
Justin Taylor
4 joint publications
Jacob Jahn
2 joint publications
Rajesh Kumar Soni
2 joint publications
Efe Karaca
2 joint publications
Maurizio Affer
2 joint publications
Daniel Bilbao
2 joint publications
Ryan Q Notti
2 joint publications
Skye Montoya
1 joint publications
Ramin Shiekhattar
1 joint publications
Juan Arango Ossa
